ID   FDFT_RAT                Reviewed;         416 AA.
AC   Q02769;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1993, sequence version 1.
DT   24-JUL-2024, entry version 162.
DE   RecName: Full=Squalene synthase;
DE            Short=SQS;
DE            Short=SS;
DE            EC=2.5.1.21 {ECO:0000269|PubMed:9575210};
DE   AltName: Full=FPP:FPP farnesyltransferase;
DE   AltName: Full=Farnesyl-diphosphate farnesyltransferase;
GN   Name=Fdft1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=1569107; DOI=10.1016/s0021-9258(18)42489-1;
RA   Shechter I., Klinger E., Rucker M.L., Engstrom R.G., Spirito J.A.,
RA   Islam M.A., Boettcher B.R., Wienstein D.B.;
RT   "Solubilization, purification, and characterization of a truncated form of
RT   rat hepatic squalene synthetase.";
RL   J. Biol. Chem. 267:8628-8635(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], CATALYTIC ACTIVITY, AND FUNCTION.
RX   PubMed=1400448; DOI=10.1016/s0021-9258(19)36619-0;
RA   McKenzie T.L., Jiang G., Straubhaar J.R., Conrad D.G., Shechter I.;
RT   "Molecular cloning, expression, and characterization of the cDNA for the
RT   rat hepatic squalene synthase.";
RL   J. Biol. Chem. 267:21368-21374(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Heart;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   SUBCELLULAR LOCATION.
RC   TISSUE=Liver;
RX   PubMed=8509416; DOI=10.1016/s0021-9258(18)31462-5;
RA   Stamellos K.D., Shackelford J.E., Schechter I., Jiang G., Conrad D.G.,
RA   Keller G.-A., Krisans S.K.;
RT   "Subcellular localization of squalene synthase in rat hepatic cells.
RT   Biochemical and immunochemical evidence.";
RL   J. Biol. Chem. 268:12825-12836(1993).
RN   [5]
RP   CATALYTIC ACTIVITY, FUNCTION, AND MUTAGENESIS OF TYR-171; TYR-174; ARG-185;
RP   GLN-283; PHE-286; PHE-288 AND GLN-293.
RX   PubMed=9575210; DOI=10.1074/jbc.273.20.12515;
RA   Gu P., Ishii Y., Spencer T.A., Shechter I.;
RT   "Function-structure studies and identification of three enzyme domains
RT   involved in the catalytic activity in rat hepatic squalene synthase.";
RL   J. Biol. Chem. 273:12515-12525(1998).
RN   [6]
RP   DISEASE.
RX   PubMed=16440058; DOI=10.1172/jci20797;
RA   Mori M., Li G., Abe I., Nakayama J., Guo Z., Sawashita J., Ugawa T.,
RA   Nishizono S., Serikawa T., Higuchi K., Shumiya S.;
RT   "Lanosterol synthase mutations cause cholesterol deficiency-associated
RT   cataracts in the Shumiya cataract rat.";
RL   J. Clin. Invest. 116:395-404(2006).
CC   -!- FUNCTION: Catalyzes the condensation of 2 farnesyl pyrophosphate (FPP)
CC       moieties to form squalene (PubMed:9575210). Proceeds in two distinct
CC       steps. In the first half-reaction, two molecules of FPP react to form
CC       the stable presqualene diphosphate intermediate (PSQPP), with
CC       concomitant release of a proton and a molecule of inorganic
CC       diphosphate. In the second half-reaction, PSQPP undergoes heterolysis,
CC       isomerization, and reduction with NADPH or NADH to form squalene. It is
CC       the first committed enzyme of the sterol biosynthesis pathway (By
CC       similarity). {ECO:0000250|UniProtKB:P37268,
CC       ECO:0000269|PubMed:9575210}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=2 (2E,6E)-farnesyl diphosphate + H(+) + NADPH = 2 diphosphate
CC         + NADP(+) + squalene; Xref=Rhea:RHEA:32295, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:15440, ChEBI:CHEBI:33019, ChEBI:CHEBI:57783,
CC         ChEBI:CHEBI:58349, ChEBI:CHEBI:175763; EC=2.5.1.21;
CC         Evidence={ECO:0000269|PubMed:9575210};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:32296;
CC         Evidence={ECO:0000269|PubMed:9575210};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=2 (2E,6E)-farnesyl diphosphate + H(+) + NADH = 2 diphosphate +
CC         NAD(+) + squalene; Xref=Rhea:RHEA:32299, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:15440, ChEBI:CHEBI:33019, ChEBI:CHEBI:57540,
CC         ChEBI:CHEBI:57945, ChEBI:CHEBI:175763; EC=2.5.1.21;
CC         Evidence={ECO:0000250|UniProtKB:P37268};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:32300;
CC         Evidence={ECO:0000250|UniProtKB:P37268};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H(+) + NADH + presqualene diphosphate = diphosphate + NAD(+) +
CC         squalene; Xref=Rhea:RHEA:22228, ChEBI:CHEBI:15378, ChEBI:CHEBI:15440,
CC         ChEBI:CHEBI:33019, ChEBI:CHEBI:57310, ChEBI:CHEBI:57540,
CC         ChEBI:CHEBI:57945; Evidence={ECO:0000250|UniProtKB:P37268};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:22229;
CC         Evidence={ECO:0000250|UniProtKB:P37268};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H(+) + NADPH + presqualene diphosphate = diphosphate + NADP(+)
CC         + squalene; Xref=Rhea:RHEA:22232, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:15440, ChEBI:CHEBI:33019, ChEBI:CHEBI:57310,
CC         ChEBI:CHEBI:57783, ChEBI:CHEBI:58349;
CC         Evidence={ECO:0000269|PubMed:9575210};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:22233;
CC         Evidence={ECO:0000269|PubMed:9575210};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=2 (2E,6E)-farnesyl diphosphate = diphosphate + presqualene
CC         diphosphate; Xref=Rhea:RHEA:22672, ChEBI:CHEBI:33019,
CC         ChEBI:CHEBI:57310, ChEBI:CHEBI:175763;
CC         Evidence={ECO:0000250|UniProtKB:P37268};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:22673;
CC         Evidence={ECO:0000250|UniProtKB:P37268};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000250|UniProtKB:P37268};
CC   -!- PATHWAY: Terpene metabolism; lanosterol biosynthesis; lanosterol from
CC       farnesyl diphosphate: step 1/3. {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:8509416}; Multi-pass membrane protein
CC       {ECO:0000255}.
CC   -!- DISEASE: Note=Defects in Lss and Fdft1 are the cause of Shumiya
CC       cataract rat (SCR). This strain develop mature cataracts at around 11
CC       weeks of age, exhibiting opacity from the perinuclear zone to the
CC       cortical intermediate layer. Cholesterol levels in cataractous lenses
CC       decreased to about 57% of normal. Cholesterol insufficiency may cause
CC       the deficient proliferation of lens epithelial cells in Shumiya
CC       cataract rats, resulting in the loss of homeostatic epithelial cell
CC       control of the underlying fiber cells and ultimately cataractogenesis.
CC       {ECO:0000269|PubMed:16440058}.
CC   -!- SIMILARITY: Belongs to the phytoene/squalene synthase family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M95591; AAA42179.1; -; mRNA.
DR   EMBL; BC081810; AAH81810.1; -; mRNA.
DR   PIR; A45105; A45105.
DR   RefSeq; NP_062111.1; NM_019238.2.
DR   AlphaFoldDB; Q02769; -.
DR   SMR; Q02769; -.
DR   STRING; 10116.ENSRNOP00000029808; -.
DR   BindingDB; Q02769; -.
DR   ChEMBL; CHEMBL3815; -.
DR   DrugCentral; Q02769; -.
DR   GuidetoPHARMACOLOGY; 645; -.
DR   PhosphoSitePlus; Q02769; -.
DR   jPOST; Q02769; -.
DR   PaxDb; 10116-ENSRNOP00000029808; -.
DR   Ensembl; ENSRNOT00000032089.5; ENSRNOP00000029808.3; ENSRNOG00000021314.5.
DR   Ensembl; ENSRNOT00065052092; ENSRNOP00065042871; ENSRNOG00065030182.
DR   GeneID; 29580; -.
DR   KEGG; rno:29580; -.
DR   UCSC; RGD:61834; rat.
DR   AGR; RGD:61834; -.
DR   CTD; 2222; -.
DR   RGD; 61834; Fdft1.
DR   eggNOG; KOG1459; Eukaryota.
DR   GeneTree; ENSGT00390000016034; -.
DR   HOGENOM; CLU_031981_0_2_1; -.
DR   InParanoid; Q02769; -.
DR   OrthoDB; 5487739at2759; -.
DR   PhylomeDB; Q02769; -.
DR   TreeFam; TF105316; -.
DR   BRENDA; 2.5.1.21; 5301.
DR   Reactome; R-RNO-191273; Cholesterol biosynthesis.
DR   UniPathway; UPA00767; UER00751.
DR   PRO; PR:Q02769; -.
DR   Proteomes; UP000002494; Chromosome 15.
DR   Bgee; ENSRNOG00000021314; Expressed in liver and 20 other cell types or tissues.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IDA:UniProtKB.
DR   GO; GO:0004310; F:farnesyl-diphosphate farnesyltransferase activity; IDA:RGD.
DR   GO; GO:0004311; F:farnesyltranstransferase activity; IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0051996; F:squalene synthase activity; IBA:GO_Central.
DR   GO; GO:0006695; P:cholesterol biosynthetic process; IMP:RGD.
DR   GO; GO:0045338; P:farnesyl diphosphate metabolic process; IMP:RGD.
DR   GO; GO:0008299; P:isoprenoid biosynthetic process; IEA:UniProtKB-KW.
DR   CDD; cd00683; Trans_IPPS_HH; 1.
DR   Gene3D; 1.10.600.10; Farnesyl Diphosphate Synthase; 1.
DR   InterPro; IPR008949; Isoprenoid_synthase_dom_sf.
DR   InterPro; IPR002060; Squ/phyt_synthse.
DR   InterPro; IPR006449; Squal_synth-like.
DR   InterPro; IPR019845; Squalene/phytoene_synthase_CS.
DR   InterPro; IPR044844; Trans_IPPS_euk-type.
DR   InterPro; IPR033904; Trans_IPPS_HH.
DR   NCBIfam; TIGR01559; squal_synth; 1.
DR   PANTHER; PTHR11626; FARNESYL-DIPHOSPHATE FARNESYLTRANSFERASE; 1.
DR   PANTHER; PTHR11626:SF2; SQUALENE SYNTHASE; 1.
DR   Pfam; PF00494; SQS_PSY; 1.
DR   SFLD; SFLDS00005; Isoprenoid_Synthase_Type_I; 1.
DR   SFLD; SFLDG01018; Squalene/Phytoene_Synthase_Lik; 1.
DR   SUPFAM; SSF48576; Terpenoid synthases; 1.
DR   PROSITE; PS01044; SQUALEN_PHYTOEN_SYN_1; 1.
DR   PROSITE; PS01045; SQUALEN_PHYTOEN_SYN_2; 1.
PE   1: Evidence at protein level;
KW   Cholesterol biosynthesis; Cholesterol metabolism; Disease variant;
KW   Endoplasmic reticulum; Isoprene biosynthesis; Lipid biosynthesis;
KW   Lipid metabolism; Magnesium; Membrane; Metal-binding;
KW   Multifunctional enzyme; NAD; NADP; Reference proteome;
KW   Steroid biosynthesis; Steroid metabolism; Sterol biosynthesis;
KW   Sterol metabolism; Transferase; Transmembrane; Transmembrane helix.
FT   CHAIN           1..416
FT                   /note="Squalene synthase"
FT                   /id="PRO_0000067445"
FT   TRANSMEM        284..304
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        384..404
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   BINDING         52
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000250|UniProtKB:P37268"
FT   BINDING         77
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000250|UniProtKB:P37268"
FT   BINDING         80
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /evidence="ECO:0000250|UniProtKB:P37268"
FT   BINDING         83
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /evidence="ECO:0000250|UniProtKB:P37268"
FT   BINDING         84
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /evidence="ECO:0000250|UniProtKB:P37268"
FT   BINDING         218
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000250|UniProtKB:P37268"
FT   BINDING         315
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000250|UniProtKB:P37268"
FT   BINDING         317
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000250|UniProtKB:P37268"
FT   MUTAGEN         171
FT                   /note="Y->F,S,W: Completely abolishes formation of PSPP or
FT                   squalene from FPP."
FT                   /evidence="ECO:0000269|PubMed:9575210"
FT   MUTAGEN         174
FT                   /note="Y->F,S,W: Has little effect on the total squalene
FT                   synthase activity."
FT                   /evidence="ECO:0000269|PubMed:9575210"
FT   MUTAGEN         185
FT                   /note="R->G: Does not affect squalene synthase activity."
FT                   /evidence="ECO:0000269|PubMed:9575210"
FT   MUTAGEN         283
FT                   /note="Q->E,N: Retains partial activity of the first
FT                   reaction. Retains partial activity of the second reaction."
FT                   /evidence="ECO:0000269|PubMed:9575210"
FT   MUTAGEN         286
FT                   /note="F->D,R: Completely eliminates the activities of both
FT                   the first and the second reactions."
FT                   /evidence="ECO:0000269|PubMed:9575210"
FT   MUTAGEN         286
FT                   /note="F->Y,W,L: Retains partial activity of the first
FT                   reaction. Retains partial activity of the second reaction."
FT                   /evidence="ECO:0000269|PubMed:9575210"
FT   MUTAGEN         288
FT                   /note="F->D,R: Completely eliminates the activities of both
FT                   the first and the second reactions."
FT                   /evidence="ECO:0000269|PubMed:9575210"
FT   MUTAGEN         288
FT                   /note="F->L: Retains partial activity of the first
FT                   reaction. Completely eliminates the activity of the second
FT                   reaction."
FT                   /evidence="ECO:0000269|PubMed:9575210"
FT   MUTAGEN         288
FT                   /note="F->Y,W,L: Retains partial activity of the first
FT                   reaction. Retains partial activity of the second reaction."
FT                   /evidence="ECO:0000269|PubMed:9575210"
FT   MUTAGEN         293
FT                   /note="Q->N,E: Retains partial activity of the first
FT                   reaction. Retains partial activity of the second reaction."
FT                   /evidence="ECO:0000269|PubMed:9575210"
SQ   SEQUENCE   416 AA;  48106 MW;  F4BC4D09C9F72169 CRC64;
     MEFVKCLGHP EEFYNLLRFR MGGRRNFIPK MDRNSLSNSL KTCYKYLDQT SRSFAAVIQA
     LDGDIRHAVC VFYLILRAMD TVEDDMAISV EKKIPLLRNF HTFLYEPEWR FTESKEKHRV
     VLEDFPTISL EFRNLAEKYQ TVIADICHRM GCGMAEFLNK DVTSKQDWDK YCHYVAGLVG
     IGLSRLFSAS EFEDPIVGED TECANSMGLF LQKTNIIRDY LEDQQEGRQF WPQEVWGKYV
     KKLEDFVKPE NVDVAVKCLN ELITNALQHI PDVITYLSRL RNQSVFNFCA IPQVMAIATL
     AACYNNHQVF KGVVKIRKGQ AVTLMMDATN MPAVKAIIYQ YIEEIYHRVP NSDPSASKAK
     QLISNIRTQS LPNCQLISRS HYSPIYLSFI MLLAALSWQY LSTLSQVTED YVQREH
//
